Clinical Trials Browser

Hemangiosarcoma, Leiomyosarcoma, Osteosarcoma, Sarcoma, Synovial, Hemangioendothelioma, Epithelioid, Vascular Neoplasms, Histiocytoma, Malignant Fibrous

NCT04774380 2025-05-23

LUMINANCE

Phase 3 Completed

152 enrolled 17 charts

Thoracic

Small Cell Lung Carcinoma

NCT02788773 2025-05-15

Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer

Phase 2 Completed

52 enrolled 12 charts

Genitourinary

Prostatic Neoplasms

NCT03618654 2025-05-15

Durvalumab With or Without Metformin in Treating Participants With Head and Neck Squamous Cell Carcinoma

Phase EARLY_PHASE1 Completed

38 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT03212469 2025-05-08

ABIMMUNE

Phase 1/2 Completed

54 enrolled

GastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Esophageal Neoplasms, Lung Neoplasms

NCT03406650 2025-05-04

SAKK 06/17

Phase 2 Completed

61 enrolled

Tumor-Agnostic

Neoplasms

NCT05239169 2025-05-01

Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer

Phase 2 Completed

40 enrolled

Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma, Klatskin Tumor

NCT05924880 2025-04-22

TopDouble

Phase 3 Completed

116 enrolled

Gastrointestinal

Biliary Tract Neoplasms

NCT04003246 2025-03-21

Phase II Concurrent Durvalumab and Radiotherapy for for Stage III Non-Small Cell Lung Cancer

Phase 2 Completed

10 enrolled 13 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02879162 2025-03-07

Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours

Phase 2 Completed

140 enrolled 9 charts

Advanced Rare Tumours

NCT03871036 2025-03-06

ICRA

Phase 1/2 Completed

53 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT04230408 2025-02-11

PACIFIC BRAZIL

Phase 2 Completed

48 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03518606 2025-01-15

MOVIE

Phase 1/2 Completed

126 enrolled

BreastGenitourinaryGynecologicHead & Neck

Breast Neoplasms, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Prostatic Neoplasms

NCT03509012 2025-01-14

CLOVER

Phase 1 Completed

105 enrolled

Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

Clinical Trials

STERIMGLI

ASTEROID

ATLANTIC

358

TRADE-hypo

Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)

Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma

CAIRE

Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours

Hepatic Artery Infusion Chemotherapy (HAIC) Plus Durvalumab for Advanced Hepatocellular Carcinoma

Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck

Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin

A Study Comparing Sotorasib With Durvalumab in People With Non-Small Cell Lung Cancer (NSCLC)

DREAM3R

Phase II Study of Durvalumab ,Doxorubicin, and Ifosfamide in Pulmonary Sarcomatoid Carcinoma

......SMARTEST Trial......

IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma

Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers

ARION

LCD

Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors

Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung Cancer

Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer

Anti-PD-L1 in Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC)

SAVIMMUNE

SEPION

Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial

Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer Patients

SKYSCRAPER-03

TRAMUNE

CTLA-4 /PD-L1 Blockade Following Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC (Hepatocellular Carcinoma) Using Durvalumab and Tremelimumab

Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies

Trial in Patients With Relapsed Ovarian Cancer

CheckMate73L

Radiotherapy With Durvalumab Prior to Surgical Resection for HPV Negative Squamous Cell Carcinoma

Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes

LUMINANCE

Durvalumab With or Without Tremelimumab in Metastatic Castration Resistant Prostate Cancer

Durvalumab With or Without Metformin in Treating Participants With Head and Neck Squamous Cell Carcinoma

ABIMMUNE

SAKK 06/17

Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer

TopDouble

Phase II Concurrent Durvalumab and Radiotherapy for for Stage III Non-Small Cell Lung Cancer

Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours

ICRA

PACIFIC BRAZIL

MOVIE

CLOVER